Real-world Safety and Effectiveness of 24-week Sofosbuvir and Ribavirin Treatment in Patients Infected with Rare Chronic Hepatitis C Virus Genotypes 3, 4, 5, or 6 in Japan.

Mita, Eiji; Liu, Lauren J; Shing, Danielle; Force, Lindsey; Aoki, Kouji; Nakamoto, Daisuke; Ishizaki, Akinobu; Konishi, Hiroki; Mizutani, Hajime; Ng, Leslie J

Mita, Eiji; Liu, Lauren J; Shing, Danielle; Force, Lindsey; Aoki, Kouji; Nakamoto, Daisuke; Ishizaki, Akinobu; Konishi, Hiroki; Mizutani, Hajime; Ng, Leslie J.

Affiliation

Mita E; National Hospital Organization Osaka National Hospital, Japan.
Liu LJ; Gilead Sciences, USA.
Shing D; Gilead Sciences International, United Kingdom.
Force L; Gilead Sciences, USA.
Aoki K; Gilead Sciences, Japan.
Nakamoto D; Gilead Sciences, Japan.
Ishizaki A; Gilead Sciences, Japan.
Konishi H; Gilead Sciences, Japan.
Mizutani H; Gilead Sciences, Japan.
Ng LJ; Gilead Sciences, USA.

Intern Med ; 62(10): 1405-1414, 2023 May 15.

Article in En | MEDLINE | ID: mdl-36047126

Subject(s)
Key words

genotype; hepatitis C; ribavirin; safety; sofosbuvir; sustained virologic response

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hepatitis C / Hepatitis C, Chronic Type of study: Observational_studies Limits: Adult / Humans Country/Region as subject: Asia Language: En Journal: Intern Med Journal subject: MEDICINA INTERNA Year: 2023 Document type: Article Affiliation country: Japón Country of publication: Japón

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google